Clinical Trials on Pandemic H5N1 Influenza in South Africa

Total 242 results

Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine

Influenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, Avian

Australia, Germany, Italy
VaxInnate Corporation

Completed

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

Influenza

United States
University of Witwatersrand, South Africa

Completed

Influenza Vaccine in HIV Infected Children

Influenza With Pneumonia, Influenza Virus Identified

South Africa
Sanofi

Completed

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

Influenza | Orthomyxoviridae Infections

United States
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B (PIPET B)

Pandemic Influenza

Australia
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza (PIPET C)

Pandemic Influenza

Australia
National Institute for Communicable Diseases, South...
Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention

Unknown

Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa

Influenza Viral Infections

South Africa
Kirby Institute
National Health and Medical Research Council, Australia

Withdrawn

A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza (PIPET A)

Pandemic Influenza

Australia
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

Influenza

South Africa
Seqirus

Completed

A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children

Influenza Caused by the Novel Influenza A (H1N1) Virus

Australia
Novavax
Department of Health and Human Services

Completed

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Influenza (Pandemic)

United States
University of Witwatersrand, South Africa
University of Colorado, Denver; Emory University; Bill and Melinda Gates Foundation

Completed

Influenza Vaccine Trial in HIV Uninfected Pregnant Women (MatfluHIVneg)

Influenza

South Africa
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1/LT Dose Ranging Study

Pandemic Influenza

United States
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation

Completed

Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women

Influenza

South Africa
Novartis Vaccines

Completed

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

Novel 2009 Influenza H1N1

Costa Rica
University of Witwatersrand, South Africa

Completed

Efficacy of Influenza Vaccine in HIV Infected Adults

HIV Infections | HIV | Influenza | Vaccination

South Africa
University of Witwatersrand, South Africa

Completed

Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women

Influenza

South Africa
University of Witwatersrand, South Africa
University of Colorado, Denver; Emory University; Bill and Melinda Gates Foundation

Completed

Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity (MatfluHIVpos)

Influenza

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years

Influenza | Swine-origin A/H1N1 Influenza

United States
University of Witwatersrand, South Africa

Completed

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (TIV_HIV_TB)

HIV | Tuberculosis | Influenza

South Africa
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (FluMist)

Influenza

South Africa
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation

Completed

Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women

Influenza | Human Immunodeficiency Virus

South Africa
Emergent BioSolutions

Completed

Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

Influenza A H3N2 | Influenza A H1N1

United States, Spain, Canada, Puerto Rico
National Institute for Communicable Diseases, South...
Centers for Disease Control and Prevention; Fogarty International Center of... and other collaborators

Active, not recruiting

Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa (PHIRST-C)

Influenza | SARS-CoV-2 Infection | Respiratory Syncytial Virus (RSV)

South Africa
GlaxoSmithKline

Completed

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

Respiratory Disorders

Australia
University of Cape Town

Completed

Health System Dynamic & Resource Requirement in a South African COVID-19 Field Hospital

COVID-19 Pandemic | Low-Income Population | Global Health | Health Resources | Field Hospitals | Health Systems

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

Australia
BioCryst Pharmaceuticals

Completed

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Influenza

United States, South Africa
GlaxoSmithKline

Completed

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis

South Africa
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)

Influenza, Avian

Australia
University of Athens
Hellenic Pasteur Institute

Completed

Influenza Vaccine Effectiveness of a Quadrivalent Vaccine in Pregnant Women and Young Infants, 2019-2020

Influenza in Human

Greece
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Novavax

Completed

A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1

Avian Influenza

Australia
Abbott Rapid Dx

Completed

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Diagnostics Jena GmbH

Completed

Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel

COVID-19 | Influenza A | Influenza Type B

United States
Abbott Rapid Dx

Completed

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Rapid Panel Professional Use Device and the Panbio™ COVID-19/Flu A&B Rapid Panel Self-Test Device

COVID-19 | Influenza A | Influenza Type B

United States
Vaxxas Pty Ltd
Biomedical Advanced Research and Development Authority

Not yet recruiting

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (HD-MAP)

H7N9 Influenza

Australia
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Hoffmann-La Roche

Completed

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

Influenza

Poland, United States, Costa Rica, Bulgaria, South Africa, Spain, Israel, Finland, Russian Federation
Emergent BioSolutions

Completed

Universal Influenza A Vaccine in Healthy Adults (EBS-UFV-001)

Human Influenza

Australia
GlaxoSmithKline

Completed

Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza

Virus Diseases

United States, South Africa, Australia

Clinical Trials on Pandemic H5N1 Influenza in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations